GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
Cell Culture Techniques
Cell Engineering
Humans
Immunologic Memory
Immunotherapy, Adoptive
NK Cell Lectin-Like Receptor Subfamily K
/ genetics
Neoplasms
/ genetics
Receptors, Chimeric Antigen
/ genetics
Recombinant Fusion Proteins
/ genetics
Tumor Necrosis Factor Receptor Superfamily, Member 9
/ genetics
CliniMACS prodigy
NKG2D CAR
automated production
clinical-grade
large-scale
memory T cells
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
13
06
2019
accepted:
19
09
2019
entrez:
26
10
2019
pubmed:
28
10
2019
medline:
30
10
2020
Statut:
epublish
Résumé
Natural killer group 2D (NKG2D) is a natural killer (NK) cell-activating receptor that recognizes different stress-induced ligands that are overexpressed in a variety of childhood and adult tumors. NKG2D chimeric antigen receptor (CAR) T cells have shown potent anticancer effects against different cancer types. A second-generation NKG2D CAR was generated by fusing full-length human NKG2D to 4-1BB costimulatory molecule and CD3ζ signaling domain. Patient-derived CAR T cells show limitations including inability to manufacture CAR T cells from the patients' own T cells, disease progression, and death prior to return of engineered cells. The use of allogeneic T cells for CAR therapy could be an attractive alternative, although undesirable graft vs. host reactions may occur. To avoid such adverse effects, we used CD45RA
Identifiants
pubmed: 31649672
doi: 10.3389/fimmu.2019.02361
pmc: PMC6795760
doi:
Substances chimiques
KLRK1 protein, human
0
NK Cell Lectin-Like Receptor Subfamily K
0
Receptors, Chimeric Antigen
0
Recombinant Fusion Proteins
0
TNFRSF9 protein, human
0
Tumor Necrosis Factor Receptor Superfamily, Member 9
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2361Informations de copyright
Copyright © 2019 Fernández, Fernández, Mirones, Escudero, Cardoso, Vela, Lanzarot, de Paz, Leivas, Gallardo, Marcos, Romero, Martínez-López and Pérez-Martínez.
Références
Front Immunol. 2019 Feb 05;10:128
pubmed: 30804938
Cancer Discov. 2015 Dec;5(12):1282-95
pubmed: 26516065
Gene Ther. 2016 Jan;23(1):113-8
pubmed: 26202078
Sci Transl Med. 2014 Feb 19;6(224):224ra25
pubmed: 24553386
Nat Med. 2008 Nov;14(11):1264-70
pubmed: 18978797
Cytotherapy. 2018 Mar;20(3):394-406
pubmed: 29287970
Clin Cancer Res. 2017 Oct 1;23(19):5824-5835
pubmed: 28659311
Front Immunol. 2018 Jul 27;9:1740
pubmed: 30140266
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
J Clin Oncol. 2016 Apr 1;34(10):1112-21
pubmed: 26811520
Cancer Gene Ther. 2015 Mar;22(2):67-71
pubmed: 25633481
Cancer Immun. 2013 May 01;13:8
pubmed: 23833565
Drug Des Devel Ther. 2018 Oct 05;12:3343-3356
pubmed: 30323566
Blood. 2012 Jan 5;119(1):72-82
pubmed: 22031866
Comput Struct Biotechnol J. 2016 Sep 28;14:357-362
pubmed: 27761200
Front Oncol. 2019 Mar 05;9:126
pubmed: 30891427
J Immunol. 2012 Aug 1;189(3):1360-71
pubmed: 22730533
Cytotherapy. 2016 Nov;18(11):1393-1409
pubmed: 27592405
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
Blood. 2007 Apr 1;109(7):3115-23
pubmed: 17148592
Sci Transl Med. 2016 Sep 7;8(355):355ra116
pubmed: 27605551
Blood. 2004 Oct 15;104(8):2403-9
pubmed: 15231569
J Clin Oncol. 2015 Feb 20;33(6):540-9
pubmed: 25154820
Blood. 2013 Oct 24;122(17):2965-73
pubmed: 24030379
Leukemia. 2004 Apr;18(4):676-84
pubmed: 14961035
Bone Marrow Transplant. 2018 Mar;53(3):264-273
pubmed: 29269793
J Hematol Oncol. 2017 Aug 29;10(1):151
pubmed: 28851445
Cancers (Basel). 2016 Mar 15;8(3):null
pubmed: 26999211
Front Immunol. 2018 Dec 12;9:2940
pubmed: 30619300
Haematologica. 2018 Sep;103(9):e424-e426
pubmed: 29703727
Annu Rev Med. 2014;65:333-47
pubmed: 24274181
Eur J Immunol. 2013 Nov;43(11):2797-809
pubmed: 24258910
PLoS One. 2012;7(2):e31210
pubmed: 22355347
Leukemia. 2015 Feb;29(2):387-95
pubmed: 24888271
Cancer Immunol Res. 2019 Jan;7(1):100-112
pubmed: 30396908
J Immunother. 2009 Feb-Mar;32(2):169-80
pubmed: 19238016
Hum Gene Ther. 2017 Oct;28(10):914-925
pubmed: 28847167
Oncoimmunology. 2016 Nov 22;5(12):e1250051
pubmed: 28123890
Cancer Lett. 2015 Nov 1;368(1):54-63
pubmed: 26276724
J Clin Invest. 2003 Jul;112(1):101-8
pubmed: 12840064
Arch Pharm Res. 2019 Jul;42(7):607-616
pubmed: 30830661
J Immunol Res. 2015;2015:473175
pubmed: 26236752
Haematologica. 2014 Jul;99(7):1248-54
pubmed: 24658822
Cytotherapy. 2013 Nov;15(11):1406-15
pubmed: 23992830
Clin Cancer Res. 2016 Apr 15;22(8):1875-84
pubmed: 27084741
Blood. 2008 Feb 15;111(4):2476-84
pubmed: 18045967
PLoS One. 2013 May 31;8(5):e64138
pubmed: 23741305
Eur J Haematol. 2014 Jun;92(6):491-6
pubmed: 24520815
Hum Gene Ther. 2013 Mar;24(3):295-305
pubmed: 23297870
Cytotherapy. 2016 Aug;18(8):1002-1011
pubmed: 27378344